{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:44:54Z","timestamp":1793407494667,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clinthera.2022.09.008","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T22:52:08Z","timestamp":1665096728000},"page":"1449-1462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease"],"prefix":"10.1016","volume":"44","author":[{"given":"Malaz","family":"Boustani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin G.","family":"Doty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Louis P.","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee J.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Belger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel","family":"Burge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3913-9256","authenticated-orcid":false,"given":"Joseph A.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.09.008_bib0001","series-title":"Reducing the Impact of Dementia in America: A Decadal Survey of the Behavioral and Social Sciences","year":"2021"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0002","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.18553\/jmcp.2021.27.11.1618","article-title":"ICER report on Alzheimer\u2019s disease: implications from a patient perspective","volume":"27","author":"Franklin","year":"2021","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0003","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.18553\/jmcp.2021.27.11.1613","article-title":"The effectiveness and value of aducanumab for Alzheimer\u2019s disease","volume":"27","author":"Synnott","year":"2021","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0004","doi-asserted-by":"crossref","first-page":"e968","DOI":"10.1212\/WNL.0000000000013314","article-title":"Cost-effectiveness and value-based pricing of aducanumab for patients with early Alzheimer\u2019s disease","volume":"98","author":"Whittington","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0005","doi-asserted-by":"crossref","first-page":"e2129392","DOI":"10.1001\/jamanetworkopen.2021.29392","article-title":"Evaluation of the cost-effectiveness of drug treatment for Alzheimer\u2019s disease in a simulation model that includes caregiver and societal factors","volume":"4","author":"Ito","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0006","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2022.0315","article-title":"Cost-effectiveness of aducanumab and donanemab for early Alzheimer\u2019s disease in the US","volume":"79","author":"Ross","year":"2022","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0007","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0008","doi-asserted-by":"crossref","unstructured":"Potashman M, Benea M, Gillis C, Gianinazzi M, Ikram MA, Maserejian N. Estimating the prevalence of A\u03b2-confirmed Alzheimer's disease using a funnel-based approach. Value in Health. 2020;23:S633\u2013S634. Abstract PND59.","DOI":"10.1016\/j.jval.2020.08.1384"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0009","unstructured":"Johnson RW. ASPE Research Brief: What Is the Lifetime Risk of Needing and Receiving Long-Term Services and Supports? Office of the Assistant Secretary for Planning and Evaluation. US Dept of Health and Human Services. April 3, 2019. Available at: https:\/\/aspe.hhs.gov\/reports\/what-lifetime-risk-needing-receiving-long-term-services-supports-0. Accessed December 2021."},{"key":"10.1016\/j.clinthera.2022.09.008_bib0010","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1212\/WNL.52.6.1138","article-title":"Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer\u2019s disease","volume":"52","author":"Neumann","year":"1999","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.clinthera.2022.09.008_bib0011","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1474-4422(06)70677-9","article-title":"Disease-modifying trials in Alzheimer\u2019s disease: a European task force consensus","volume":"6","author":"Vellas","year":"2007","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0012","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0013","doi-asserted-by":"crossref","unstructured":"Swanson C, Dhadda S, Irizarry M, et al. Clinical, Biomarker, and Safety Update from the Lecanemab Phase 2 Study. Lecanemab: An Assessment of the Clinical Effects, the Correlation of Plasma AB 42\/40 Ratio with Changes in Brain Amyloid PET SUVr, and Safety from the Core and Open Label Extension of the Phase 2 Proof-of-Concept Study, BAN2401-G000-201, in Subjects with Early Alzheimer's Disease. Paper presented at: Annual Meeting of Clinical Trials on Alzheimer's Disease; November 2021; Boston,MA.","DOI":"10.1002\/alz.057760"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0014","unstructured":"Food and Drug Administration Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee. Combined FDA and Applicant PCNS Drugs Advisory Committee Briefing Document: Aducanumab. November 6, 2020. Available at: https:\/\/www.fda.gov\/media\/143502\/download. Accessed December 2021."},{"key":"10.1016\/j.clinthera.2022.09.008_bib0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Haeberlein","year":"2022","journal-title":"The Journal of Prevention of Alzheimer\u2019s Disease"},{"issue":"15 Supplement","key":"10.1016\/j.clinthera.2022.09.008_bib0016","article-title":"Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer\u2019s disease (S2.004)","volume":"90","author":"Haeberlein","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0017","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer\u2019s Research & Therapy"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0018","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00005650-199901000-00005","article-title":"Health utilities in Alzheimer\u2019s disease: a cross-sectional study of patients and caregivers","volume":"37","author":"Neumann","year":"1999","journal-title":"Medical Care"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0020","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11136-010-9783-5","article-title":"EuroQol (EQ-5D) health utility scores for patients with migraine","volume":"20","author":"Xu","year":"2011","journal-title":"Quality of Life Research"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0021","unstructured":"Biogen Investor Relations. Biogen announces reduced price for Aduhelm to improve access for patients with early Alzheimer's Disease. Available at: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-announces-reduced-price-aduhelmr-improve-access-patients. Accessed April 12, 2022."},{"key":"10.1016\/j.clinthera.2022.09.008_bib0022","unstructured":"Centers for Medicare and Medicaid Services. Clinical Physician Fee Schedule Files. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search\/documentation."},{"key":"10.1016\/j.clinthera.2022.09.008_bib0023","unstructured":"Medi-Span PriceRx. Accessed February 23, 2022."},{"key":"10.1016\/j.clinthera.2022.09.008_bib0024","unstructured":"The New IDEAS Study. Medicare Reimbursement for Amyloid PET Scans. Accessed April 1, 2022. https:\/\/www.ideas-study.org\/During-Study\/Medicare-Reimbursement."},{"key":"10.1016\/j.clinthera.2022.09.008_bib0025","series-title":"Aducanumab for Alzheimer's Disease: Effectiveness and Value. Final Evidence Report and Meeting Summary","year":"2021"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0026","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jalz.2015.01.007","article-title":"Direct medical costs and source of cost differences across the spectrum of cognitive decline: a population-based study","volume":"11","author":"Leibson","year":"2015","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0027","unstructured":"Administration on Aging. Costs of Care. Accessed December 13, 2021. https:\/\/acl.gov\/ltc\/costs-and-who-pays\/costs-of-care."},{"key":"10.1016\/j.clinthera.2022.09.008_bib0028","series-title":"Table B-3. Average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector, seasonally adjusted - 2022 Q01 Results","year":"2022"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0029","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3233\/JAD-191212","article-title":"Costs of early stage Alzheimer\u2019s disease in the United States: cross-sectional analysis of a prospective cohort study (GERAS-US)","volume":"75","author":"Robinson","year":"2020","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0030","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/156720510791162430","article-title":"Cross sectional observational study on the societal costs of Alzheimer\u2019s disease","volume":"7","author":"Mesterton","year":"2010","journal-title":"Current Alzheimer Research"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0031","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness \u2014 the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0032","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/13696998.2021.1927747","article-title":"Modelling the value of innovative treatments for Alzheimer\u2019s disease in the United States","volume":"24","author":"Makin","year":"2021","journal-title":"Journal of Medical Economics"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0033","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40120-021-00273-0","article-title":"Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer\u2019s disease","volume":"10","author":"Herring","year":"2021","journal-title":"Neurology and Therapy"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0034","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s40273-019-00788-3","article-title":"Family and caregiver spillover effects in cost-utility analyses of Alzheimer\u2019s disease interventions","volume":"37","author":"Lin","year":"2019","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jagp.2014.08.005","article-title":"Worsening cognitive impairment and neurodegenerative pathology progressively increase risk for delirium","volume":"23","author":"Davis","year":"2015","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0036","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jhm.1949","article-title":"Delirium in hospitalized patients: implications of current evidence on clinical practice and future avenues for research\u2014a systematic evidence review","volume":"7","author":"Khan","year":"2012","journal-title":"Journal of Hospital Medicine"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0037","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1377\/hlthaff.2018.05154","article-title":"An Alternative Payment Model To Support Widespread Use Of Collaborative Dementia Care Models","volume":"38","author":"Boustani","year":"2019","journal-title":"Health Affairs (Project Hope)"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0038","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1377\/hlthaff.2013.1221","article-title":"Healthy Aging Brain Center improved care coordination and produced net savings","volume":"33","author":"French","year":"2014","journal-title":"Health Affairs (Project Hope)"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0039","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care-a health economics approach: an ISPOR Special Task Force Report","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value in Health"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0041","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.jtho.2016.08.138","article-title":"Incremental innovation and progress in advanced squamous cell lung cancer: current status and future impact of treatment","volume":"11","author":"Langer","year":"2016","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0042","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jval.2020.10.003","article-title":"Health technology assessment with diminishing returns to health: the generalized risk-adjusted cost-effectiveness (GRACE) approach","volume":"24","author":"Lakdawalla","year":"2021","journal-title":"Value in Health"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0043","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/alz.12578","article-title":"Projecting the long-term societal value of a disease-modifying treatment for Alzheimer\u2019s disease in the United States","volume":"18","author":"Prados","year":"2022","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.clinthera.2022.09.008_bib0044","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000265553","article-title":"Very mild to severe dementia and mortality: a 14-year follow-up - the Odense study","volume":"29","author":"Andersen","year":"2010","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1016\/j.clinthera.2022.09.008_bib45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/alz.12328","article-title":"2021 Alzheimer\u2019s disease facts and figures","volume":"17","year":"2021","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.clinthera.2022.09.008_bib46","unstructured":"Lin GA, Whittington MD, Synnott PG, et al. Aducanumab for Alzheimer...s Disease: Effectiveness and Value; Final Evidence Report and Meeting Summary, Institute for Clinical and Economic Review, August 5, 2021. https:\/\/icer.org\/assessment\/alzheimers-disease-2021\/."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822003228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822003228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:58:04Z","timestamp":1758963484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822003228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0149291822003228"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.09.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Eli Lilly and Company. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}